21 patients in limbo as talks on funding life-saving drug Respreza break down

Irish patients are set to lose access to life-saving lung disease drug Respreza.

Talks on funding Respreza have collapsed between the HSE and CSL Behring, the pharmaceutical company which makes it.

Twenty-one people suffering from a genetic lung disease called Alpha 1 have been using it for more than 11 years.

They were told last Friday that they will lose access to a vital drug called Respreeza at the end of the month.

Patient Gerry Finnerty from Kinsealy in North Dublin, who is 59, said: "Nobody knows what's going to happen to (us).

"There's no drug there even to ease you off - there's just a striaght trap door: 'There: it's done'."

In a statement last week CSL Behring said: “We remain committed to AATD research to improve the quality of life of people living with the condition. Based on this commitment, we are currently in discussion with health authorities in both the US and Europe to finalise a randomised, non-placebo controlled study design which seeks to demonstrate the long-term safety and efficacy of Respreeza.

“CSL Behring is evaluating clinical sites in Ireland which may then be offered the opportunity to recruit severe AATD patients.”

More in this Section

€250k and €60k prizes won in Lotto but no winner of €2m jackpot

One person critical, five injured after Cork crash

Investigation underway after body of man, 20, found in Sligo

Vigil held outside Dublin's GPO to show support for Syrian people


Today's Stories

€160m Cork docklands plan cleared for development

€22bn green plan but TDs drive diesel

New cancer treatment to reduce radiation risk to heart

Cork one of cities worst-hit if globe heats up

Lifestyle

The biggest cancer killer will take your breath away

Hopefully she had an idea...

Power of the press: Meryl Streep and Tom Hanks discuss 'The Post'

More From The Irish Examiner